Building a roadmap for developing combination therapies for Alzheimer's disease

Daniel Perry; Reisa Sperling; Russell Katz; Donald Berry; David Dilts; Debra Hanna; Stephen Salloway; John Q. Trojanowski; Chas Bountra; Michael Krams; Johan Luthman; Steven Potkin; Val Gribkoff; Robert Temple; Yaning Wang; Maria C. Carrillo; Diane Stephenson; Heather Snyder; Enchi Liu; Tony Ware; John Mckew; F. Owen Fields; Lisa J. Bain; Cynthia Bens

doi:10.1586/14737175.2015.996551

Building a roadmap for developing combination therapies for Alzheimer's disease

Daniel Perry, Reisa Sperling, Russell Katz, Donald Berry, David Dilts, Debra Hanna, Stephen Salloway, John Q. Trojanowski, Chas Bountra, Michael Krams, Johan Luthman, Steven Potkin, Val Gribkoff, Robert Temple, Yaning Wang, Maria C. Carrillo, Diane Stephenson, Heather Snyder, Enchi Liu, Tony WareJohn Mckew, F. Owen Fields, Lisa J. Bain, Cynthia Bens

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.

Original language	English (US)
Pages (from-to)	327-333
Number of pages	7
Journal	Expert Review of Neurotherapeutics
Volume	15
Issue number	3
DOIs	https://doi.org/10.1586/14737175.2015.996551
State	Published - Mar 1 2015

Keywords

Alzheimer' disease
co-development
collaboration
combination therapy
novel therapy

ASJC Scopus subject areas

General Neuroscience
Clinical Neurology
Pharmacology (medical)

Access to Document

10.1586/14737175.2015.996551

Cite this

Perry, D., Sperling, R., Katz, R., Berry, D., Dilts, D., Hanna, D., Salloway, S., Trojanowski, J. Q., Bountra, C., Krams, M., Luthman, J., Potkin, S., Gribkoff, V., Temple, R., Wang, Y., Carrillo, M. C., Stephenson, D., Snyder, H., Liu, E., ... Bens, C. (2015). Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Review of Neurotherapeutics, 15(3), 327-333. https://doi.org/10.1586/14737175.2015.996551

Perry, D, Sperling, R, Katz, R, Berry, D, Dilts, D, Hanna, D, Salloway, S, Trojanowski, JQ, Bountra, C, Krams, M, Luthman, J, Potkin, S, Gribkoff, V, Temple, R, Wang, Y, Carrillo, MC, Stephenson, D, Snyder, H, Liu, E, Ware, T, Mckew, J, Fields, FO, Bain, LJ & Bens, C 2015, 'Building a roadmap for developing combination therapies for Alzheimer's disease', Expert Review of Neurotherapeutics, vol. 15, no. 3, pp. 327-333. https://doi.org/10.1586/14737175.2015.996551

@article{9985a3607eb44e2ab9fc4a90c5a61667,

title = "Building a roadmap for developing combination therapies for Alzheimer's disease",

abstract = "Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.",

keywords = "Alzheimer' disease, co-development, collaboration, combination therapy, novel therapy",

author = "Daniel Perry and Reisa Sperling and Russell Katz and Donald Berry and David Dilts and Debra Hanna and Stephen Salloway and Trojanowski, {John Q.} and Chas Bountra and Michael Krams and Johan Luthman and Steven Potkin and Val Gribkoff and Robert Temple and Yaning Wang and Carrillo, {Maria C.} and Diane Stephenson and Heather Snyder and Enchi Liu and Tony Ware and John Mckew and Fields, {F. Owen} and Bain, {Lisa J.} and Cynthia Bens",

note = "Publisher Copyright: {\textcopyright} Informa UK, Ltd.",

year = "2015",

month = mar,

day = "1",

doi = "10.1586/14737175.2015.996551",

language = "English (US)",

volume = "15",

pages = "327--333",

journal = "Expert Review of Neurotherapeutics",

issn = "1473-7175",

publisher = "Expert Reviews Ltd.",

number = "3",

}

TY - JOUR

T1 - Building a roadmap for developing combination therapies for Alzheimer's disease

AU - Perry, Daniel

AU - Sperling, Reisa

AU - Katz, Russell

AU - Berry, Donald

AU - Dilts, David

AU - Hanna, Debra

AU - Salloway, Stephen

AU - Trojanowski, John Q.

AU - Bountra, Chas

AU - Krams, Michael

AU - Luthman, Johan

AU - Potkin, Steven

AU - Gribkoff, Val

AU - Temple, Robert

AU - Wang, Yaning

AU - Carrillo, Maria C.

AU - Stephenson, Diane

AU - Snyder, Heather

AU - Liu, Enchi

AU - Ware, Tony

AU - Mckew, John

AU - Fields, F. Owen

AU - Bain, Lisa J.

AU - Bens, Cynthia

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.

AB - Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.

KW - Alzheimer' disease

KW - co-development

KW - collaboration

KW - combination therapy

KW - novel therapy

UR - http://www.scopus.com/inward/record.url?scp=84923331513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923331513&partnerID=8YFLogxK

U2 - 10.1586/14737175.2015.996551

DO - 10.1586/14737175.2015.996551

M3 - Article

C2 - 25708309

AN - SCOPUS:84923331513

SN - 1473-7175

VL - 15

SP - 327

EP - 333

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

IS - 3

ER -

Building a roadmap for developing combination therapies for Alzheimer's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this